| Literature DB >> 27768093 |
B Lipe1, R Vukas2, J Mikhael3.
Abstract
Multiple myeloma is the second most common type of blood cancer and remains incurable despite advances in therapy. Current therapy for multiple myeloma includes a phased-approach, often consisting of initial induction therapy, consolidation and maintenance therapy. With an ever-growing landscape of treatment options, the approach to optimal therapy has become increasingly complex. Specifically, controversy surrounds the optimal use and duration of maintenance therapy. We conducted a comprehensive literature search to analyze the most current literature and to provide recommendations for maintenance therapy in multiple myeloma.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27768093 PMCID: PMC5098261 DOI: 10.1038/bcj.2016.89
Source DB: PubMed Journal: Blood Cancer J ISSN: 2044-5385 Impact factor: 11.037